Prospective randomized pilot trial comparing prophylactic and therapeutic cerebrospinal fluid drainage during complex endovascular thoracoabdominal aortic aneurysm repair
- PMID: 38614137
- DOI: 10.1016/j.jvs.2024.02.041
Prospective randomized pilot trial comparing prophylactic and therapeutic cerebrospinal fluid drainage during complex endovascular thoracoabdominal aortic aneurysm repair
Abstract
Background: Endovascular techniques have transformed the management of thoracoabdominal aortic aneurysms (TAAAs). However, spinal cord ischemia (SCI) remains a prevalent and devastating complication. Prophylactic drainage of cerebrospinal fluid (CSF) is among the proposed strategies for prevention of SCI. Although prophylactic CSF drainage is widely used and conceptually attractive, prophylactic CSF drains have not been demonstrated to definitively prevent the occurrence nor mitigate the severity of SCI in endovascular TAAA repair. Whether or not outcomes of prophylactic drains are superior to therapeutic drains remains unknown. This pilot study was performed to determine the feasibility of a randomized clinical trial designed to investigate the role of prophylactic vs therapeutic CSF drains in the prevention of SCI in patients undergoing endovascular TAAA repair using branched and fenestrated endovascular aortic repair (FBEVAR).
Methods: This was a prospective multicenter randomized pilot clinical trial conducted at The University of Alabama at Birmingham and The University of Massachusetts. Twenty patients were enrolled and randomized to either the prophylactic drainage or therapeutic drainage groups, prior to undergoing FBEVAR for extensive TAAAs and arch aortic aneurysms. This was a pilot feasibility study that was not powered to detect statistical differences in clinical outcomes. The primary outcome was feasibility of randomization and compliance with a shared lumbar drain protocol. Secondary outcomes included rate of drain complications and SCI.
Results: Twenty patients were enrolled and successfully randomized, without any crossovers, to either the control cohort (n = 10), without prophylactic drains, or the experimental cohort (n = 10), with prophylactic drains. There were no differences in age, comorbidities, or history of prior aortic surgery across the cohorts. All patients were treated with FBEVAR. Aneurysm classifications were as follows: Extent I (10%), Extent II (50%), Extent III (35%), and Extent IV (5%). The average length of aortic coverage was 207 ± 21.6 mm. The length of aortic coverage did not vary across cohorts, nor did procedural times or blood loss volume. Compliance with the SCI prevention protocol was 100% across both groups. Within the prophylactic drain cohort, one patient experienced an adverse event related to lumbar drain placement, manifested as an epidural hematoma requiring laminectomy, without neurologic deficit (n = 1/10; 10%). There was one SCI event (n = 1/20; 5%), which occurred in the prophylactic drain cohort on postoperative day 9 following an episode of hypotension related to a gastrointestinal bleed.
Conclusions: The role of prophylactic CSF drains for the prevention of SCI following endovascular TAAA repair is a topic of ongoing research, with many current practices based on expert opinion and experience, rather than rigorous scientific data. This study demonstrates the feasibility of a multicenter randomized clinical trial to evaluate the role of prophylactic vs therapeutic CSF drains in the prevention of SCI in patients undergoing endovascular TAAA repair.
Keywords: Cerebrospinal fluid (CSF) drain; Clinical trial; Crawford extent; Fenestrated endovascular aortic repair (FEVAR); Spinal cord injury; Spinal cord ischemia (SCI); Thoracoabdominal aortic aneurysm (TAAA).
Copyright © 2024 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosures A.B. reports research support from Cook Medical, Endospan, Medtronic, Philips, Terumo, W.L. Gore & Associates; and consulting for Artivion, Cook Medical, Philips, Terumo (all funds to University of Alabama Birmingham). M.S. reports consulting with Artivion, Medtronic, and Gore. A.S. reports consulting for Cook, Artivion, Phillips (all compensation to UMass Foundation). G.O. reports consulting for Gore, Cook, GE Healthcare, and Centerline Biomedical; and research for GE Healthcare. C.T. reports consulting and research support from Cook Medical Inc, Philips, and W.L. Gore. J.O.J. reports grants from National Institutes for Health, Department of Defense, Medical Technology Enterprise Consortium, and National Institute for Health and Care Research; study support from Infrascan and CSL Behring; consultant for CSL Behring, Infrascan, Cellphire, and Octapharma.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
